AMRI and Proteros Ally to Offer Combined Drug Discovery and Structural Analysis Services
Firms will join complementary capabilities for biotech and pharma industries worldwide.
Albany Molecular Research (AMRI) and Proteros Biostructures announced a strategic alliance that will enable them to jointly offer their respective drug discovery and protein crystallization/x-ray structural analysis services to the life science industry.
Germany-based Proteros specializes in x-ray protein structure analysis. The firm offers a range of products and services. These include: custom gene-to structure projects, screening proteins for primary and secondary screening, biochemical assay development services, and what it claims is the largest collection of gallery structures, established as a catalog of ready-to-use drug targets for analysis as 2-D complex structures with drug candidates.
AMRI offers drug discovery and development, project management, and API/intermediates manufacturing services to clients worldwide. The firm is in addition developing an in-house pipeline of early clinical- and preclinical-stage candidates for a range of therapeutic fields, which it aims to progress in collaboration with strategic partners.